Thursday February 5, 11:36 am Eastern Time
Company Press Release
SOURCE: Inflazyme Pharmaceuticals Ltd.
Inflazyme Announces Positive Pre-clinical Results On IPL 423 (Bispan)
RICHMOND, B.C., Feb. 5 /CNW-PRN/ - Inflazyme Pharmaceuticals Ltd., (VSE: IZP; OTC - BB: IZYPF) announces
positive pre-clinical results on IPL 423 (Bispan), the company's therapeutic candidate for the treatment of rheumatoid arthritis.
Inflazyme used a mouse ear inflammation model, a standard in vivo assay for the testing of novel drugs targeted at rheumatoid
arthritis. The model involves a severe edema of tissues and release of chemical mediators responsible for inflammatory
conditions.
IPL 423 (Bispan) is a proprietary small molecule from a series of novel compounds that inhibit inflammatory cell activation in a
unique way. This class of compounds, in contrast to most other anti-inflammatory agents, activates and increases the level of a
specific protein within cell cytoplasm known as kinases. One such kinase is an internal regulator of nuclear binding proteins
known as transcription factors. Transcription factors regulate the function of genes involved in inflammation via production of
cytokines and other mediators of inflammation. IPL 423 (Bispan) activates the kinase that is working upstream of the
transcription factors involved in inflammation, thus preventing inflammatory cells from responding to inflammatory agents.
The mouse ear inflammation model is a standard in vivo assay, which produces the characteristics of human inflammation. The
inflammation is associated with an increase in ear weight which is attributable to inflammatory-mediated edema and
inflammatory cell migration to the site. The mice were separated into groups and tagged. The ''Control'' group received RTX
solution on the ear, which causes severe inflammation. The ''Experimental'' group received RTX and our drug, IPL 423
(Bispan) solution (50 ug/ear) on the ear in the form of cream. After 30 minutes, the level of inflammation and edema was
assessed, and the data were analyzed by taking the difference between the treated species and non-treated species, calculating
the mean +/-SEM and then calculating the % inhibition of edema. IPL 423 (Bispan) inhibited edema and inflammation by 91%
+/-3%.
''Since the current anti-inflammatory drugs are under constant pressure by the consumers because of their lack of effectiveness
and increased side effects, they will be replaced by novel more effective drugs with less side effects. Inflazyme is pleased to be
able to introduce several of these novel products which are shown to possess superior potency with less side effects,'' said Dr.
Hassan Salari, President & CEO. ''The company will continue to maintain a lead in the discovery and development of novel
products with unique sites of action for a variety of inflammatory diseases,'' added Dr. Hassan Salari.
Inflazyme is an emerging biopharmaceutical company focussed on the discovery and development of drugs that act through the
regulation of gene expression and biochemical pathways involved in inflammatory diseases. Inflayme's lead product IPL 576,
(Apanol) which is targeted for the treatment of asthma, is an inhibitor of transcription factor NF-kB. IPL 576 (Apanol) has
shown a potent anti-asthmatic activity in several animal models of asthma when the drug was used orally. IPL 576 (Apanol) is
currently in the late stages of toxicology testing prior to clinical trials. Inflazyme's third class of anti-inflammatory compounds,
IPL 400, is targeted for the topical treatment of psoriasis.
The statements made in this press release may contain certain forward-looking comments. Actual events or results may differ
from the Company's expectations. In addition to the matters described in this press release, future actions by the Food and
Drug Administration or equivalent regulatory authorities in various countries, results of pending or future clinical trials, as well as
such factors from time to time in the Company's SEC reports, may affect the actual results achieved by the Company.
Exemption from registration pursuant to Rule 12g 3-2(b), Reg. No. 82-2317.
The Vancouver Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this
release.
SOURCE: Inflazyme Pharmaceuticals Ltd. |
